agilon health
agilon health's revenue fell 2.1% to $5.9 billion in fiscal 2025. Its operating margin was −7.8%, down from −4.8% a year earlier. Free cash flow was −$119 million. The diluted share count rose 0.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What agilon health does
agilon health works with independent primary care physician groups that treat older Americans, mostly those in Medicare Advantage, the private plans that run Medicare. It gives these groups technology, staff, processes and capital, so they can take responsibility for their patients' total healthcare costs and quality of care. As of December 31, 2025, it had 28 partner physician groups in 30 geographies across the United States.
agilon sets up a local company in each area. That company signs contracts with health plans, which pay a set monthly fee for each member. The company is then responsible for the members' medical costs. The company also signs long-term agreements, typically lasting 20 years, with its partner physician groups. The groups receive a base payment for their services and share in savings when care improves and costs fall. If medical costs run above the fees, agilon bears the loss.
The physicians on its platform serve about 511,000 Medicare Advantage members. agilon also takes part in federal Medicare programs for people on traditional Medicare, through nine accountable care organizations, which are groups of providers that share responsibility for the cost and quality of care. It says it competes with other organizations that offer similar support to physician groups.
Its biggest risks, as it describes them
- Failing to find and add new geographies, physician groups and health plans, or to carry out its growth plans.
- Medical costs for its members that run higher than the fees it receives to pay for their care.
- Depending on a small number of health plans, whose contracts run for limited terms and may not be renewed.
- A history of net losses and a need for more money that may not be available on acceptable terms.
- Changes to Medicare payment rules and models, or audits and investigations by the government or health plans.
Income statement
agilon health lost money in fiscal 2025: a net loss of $391 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 1,040 | 877 | 488 | 400 | 285 |
| Debt incl. finance leases | 49 | 44 | 39 | 35 | 35 |
| Net debt (negative means net cash) | −991 | −833 | −450 | −365 | −250 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.1x | 0.1x | 0.3x |
| Interest coverage | −60.6x | −23.5x | −34.9x | −47.3x | −69.8x |
| Current ratio | 3.8x | 2.7x | 1.5x | 1.3x | 1.0x |
| Quick ratio | 3.8x | 2.7x | 1.5x | 1.3x | 1.0x |
Cash flow
Projections
Project agilon health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What agilon health says to expect
- Fiscal year 2026: ACO model adjusted EBITDA contribution
Adjusted EBITDA contribution from ACO model entities is expected to be approximately $40-$45 million for fiscal year 2026.
Insider trades
No officer, director or 10% owner of agilon health reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 8 | 4 of 8 | 1 of 8 |
| Rule of 40 | 76.8% | 39.2% | −4.1% |
| Altman Z'' | −0.84 | −2.57 | −7.30 |
| Accruals ratio | −6.2% | −11.7% | −19.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 3 of 8 | 4 of 8 | 1 of 8 |
Compare
Put agilon health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| agilon health | FY25 | −2.1% | −7.8% | −2.0% | — | — | 1 | |
| Alignment Healthcare | FY25 | 46.1% | 0.4% | 2.9% | — | −6.2x | 5 | Compare |
| Quest Diagnostics | FY25 | 11.8% | 14.1% | 12.3% | 9.5% | 2.5x | 6 | Compare |
| Amn Healthcare Services | FY25 | −8.5% | −2.0% | 8.6% | −2.8% | 7.2x | 5 | Compare |
| BrightSpring Health Services | FY25 | 28.2% | 2.3% | 3.1% | 5.2% | 5.3x | 7 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 794 | 1,218 | 1,522 | 2,388 | 4,316 | 6,060 | 5,933 |
| Revenue growth | — | 53.4% | 24.9% | 57.0% | 80.7% | 40.4% | −2.1% |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | — | — | — | — | — | — | — |
| Operating income | −107 | −57 | −372 | −105 | −232 | −292 | −463 |
| Net income | −283 | −60 | −406 | −107 | −263 | −260 | −391 |
| Diluted EPS (US$) | — | −0.20 | −1.03 | −0.22 | −0.48 | −0.61 | −0.98 |
| Diluted shares (millions) | 295 | 324 | 373 | 408 | 409 | 411 | 414 |
| Cash flow | |||||||
| Cash from operations | −104 | −53 | −148 | −131 | −156 | −58 | −106 |
| Capital expenditure | 3 | 2 | 7 | 15 | 16 | 13 | 13 |
| Free cash flow | −107 | −55 | −155 | −146 | −172 | −71 | −119 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 7 | 0 | 0 | 200 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 45 | 0 | 0 |
| Stock-based compensation | 5 | 7 | 292 | 28 | 70 | 51 | 49 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 139 | 107 | 1,040 | 877 | 488 | 400 | 285 |
| Debt incl. finance leases | — | 68 | 49 | 44 | 39 | 35 | 35 |
| Total assets | — | 446 | 1,586 | 1,698 | 1,741 | 1,734 | 1,271 |
| Total liabilities | — | 422 | 495 | 657 | 1,080 | 1,263 | 1,145 |
| Shareholders' equity | −232 | −285 | 1,092 | 1,041 | 662 | 471 | 127 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | −13.4% | −4.7% | −24.5% | −4.4% | −5.4% | −4.8% | −7.8% |
| Net margin | −35.6% | −4.9% | −26.7% | −4.5% | −6.1% | −4.3% | −6.6% |
| Free cash flow margin | −13.4% | −4.5% | −10.2% | −6.1% | −4.0% | −1.2% | −2.0% |
| Rule of 40 (growth + FCF margin) | — | 48.9% | 14.7% | 50.8% | 76.8% | 39.2% | −4.1% |
| Return on capital | — | — | — | — | −87.7% | — | — |
| Return on equity | — | — | −100.7% | −10.0% | −30.8% | −45.9% | −130.9% |
| Return on assets | — | — | −40.0% | −6.5% | −15.3% | −15.0% | −26.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — |